Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login

YBX2 in Cancer: From Germ Cell Gene to Oncogenic Regulator

Cyagen Technical Content Team | September 09, 2025
Ybx2-KO (C57BL/6JCya-Ybx2em1/Cya) Mouse Model
Ybx2-KO (C57BL/6JCya-Ybx2em1/Cya) mouse model. Key genetic feature: conventional Ybx2 knockout.
Ybx2-KO (C57BL/6JCya-Ybx2em1/Cya) Mouse Model
Contents
01. Overview of YBX2 Gene 02. Diseases Associated with the YBX2 Gene 03. To Be Continued: Mouse Models of Ybx2 04. References

Gene expression is controlled at numerous levels with the help of regulatory proteins. These regulatory proteins, which include transcription factors, bind to DNA and send signals that influence the rate of gene transcription by RNA. Gene regulator proteins are divided into two types: enhancers (up-regulators) and inhibitors (down-regulators), which respectively refer to proteins that lead to either an increase or decrease in the expression of a gene. Although the gene YBX2 is not the direct cause of cancer, it seems to be inextricably linked to cancer, and the latest research shows that high YBX2 expression is unfavorable in prognosis of endometrial cancer.

Overview of YBX2 Gene

YBX2 (Y-Box Binding Protein 2) is a Protein Coding gene that encodes a nucleic acid binding protein which is highly expressed in germ cells. The encoded YBX2 protein binds to a Y-box element in the promoters of certain genes but also binds to mRNA transcribed from these genes. Pseudogenes for this gene are located on chromosome 10 and 15. An important paralog of this gene is YBX3.

Protein Function

YBX2 is a germ cell-specific Y-box-binding protein. It is expressed in the germ cells of adult testes and in developing fetal testes and ovaries, but not in any other normal tissues. The function of YBX2 includes the storage and translation of mRNAs in germ cells. The YBX2 gene is expressed in early embryogenesis; however, little is known about its function. Kohno et al. reported that YBX2 is expressed in the placenta, in germ cell tumors and various human carcinomas. Its restricted pattern of expression suggests that it might be associated with cancer/testis antigens (CTAs). [2]

AlphaFold structure prediction (YBX2) (Source: Uniprot)
Figure 1. AlphaFold structure prediction (YBX2) (Source: Uniprot)

Diseases Associated with the YBX2 Gene

Human endometrial cancer (EC)

Human endometrial cancer (EC) is the most common gynaecological malignancy affecting women in the developed world. The exact cause of endometrial cancer is not known. An increased level of estrogen hormone may play a role, as this stimulates the buildup of the uterine lining. This may ultimately lead to abnormal overgrowth of the endometrium and cancer. Most cases of endometrial cancer occur between the ages of 60 to 70, and some cases may occur before age 40.

Izumi Suzuki et al. report data helped clarify the function of YBX2 in endometrial cancer stem cells. Endometrial cancer survival analysis plot shows YBX2 is a valuable prognostic market, with high expression being unfavorable in endometrial cancer.

Endometrial cancer survival analysis plot [3]
Figure 2. Endometrial cancer survival analysis plot [3]

Oral squamous cell carcinoma (OSCC)

Oral squamous cell carcinoma (OSCC) is the most common type of oral cancer; it involves damage to oral epithelial cells due to accumulation of multiple genetic mutations in the cells. OSCC remains a major cause of morbidity and mortality in patients with head and neck cancers. Consumption of alcohol, smoking tobacco, and chewing tobacco (with betel quid) are all potential carcinogens contributing to the high occurrence of OSCC. [4]

Xingyu Niu et al. examines the relationship among HOXA11-AS, miR-98-5p and YBX2 through the published experiments. They discovered the HOXA11-AS/miR-98-5p/YBX2 axis that provides a new therapeutic target for OSCC.

YBX2 level was regulated by HOXA11-AS and miR-98-5p [5]
Figure 3. YBX2 level was regulated by HOXA11-AS and miR-98-5p [5]
HOXA11-AS was highly expressed in OSCC tissues and cells. Knockdown of HOXA11-AS significantly reduced proliferation, migration, invasion and EMT, while promoting apoptosis of OSCC cells. MiR-98-5p was a target of HOXA11-AS, and its inhibitor could revert the inhibition effect of silenced-HOXA11-AS on the progression of OSCC. Also, YBX2 was a target of miR-98-5p, and its overexpression could invert the suppression effect of miR-98-5p overexpression on the progression of OSCC. YBX2 expression was regulated by HOXA11-AS and miR-98-5p. Furthermore, HOXA11-AS silencing could reduce the tumor growth of OSCC in vivo.[5]

To Be Continued: Mouse Models of Ybx2

Visit the next article below, in which we provide details on the applications of mouse models used for Ybx2 gene studies and new research progress.

References

[1] https://www.genecards.org/cgi-bin/carddisp.pl?gene=YBX2

[2] Suzuki I, Yoshida S, Tabu K, Kusunoki S, Matsumura Y, Izumi H, Asanoma K, Yagi H, Onoyama I, Sonoda K, Kohno K, Taga T, Itakura A, Takeda S, Kato K. YBX2 and cancer testis antigen 45 contribute to stemness, chemoresistance and a high degree of malignancy in human endometrial cancer. Sci Rep. 2021 Feb 18;11(1):4220. doi: 10.1038/s41598-021-83200-5. PMID: 33602962; PMCID: PMC7893073.

[3] https://www.proteinatlas.org/ENSG00000006047-YBX2/pathology/endometrial+cance

[4] Gharat SA, Momin M, Bhavsar C. Oral Squamous Cell Carcinoma: Current Treatment Strategies and Nanotechnology-Based Approaches for Prevention and Therapy. Crit Rev Ther Drug Carrier Syst. 2016;33(4):363-400. doi: 10.1615/CritRevTherDrugCarrierSyst.2016016272. PMID: 27910740.

[5] Niu X, Yang B, Liu F, Fang Q. LncRNA HOXA11-AS promotes OSCC progression by sponging miR-98-5p to upregulate YBX2 expression. Biomed Pharmacother. 2020 Jan;121:109623. doi: 10.1016/j.biopha.2019.109623. Epub 2019 Nov 12. PMID: 31731187.

Subscribe to Receive Updates & Promotions From Cyagen
Subscribe
* Your privacy matters to us. We never share it with third parties.
Explore More
In Vivo CAR-T Enters Clinical Validation: How It Works and What Comes Next
Beyond Subretinal Injections: How AI is Reshaping AAV Capsid Engineering for Retinal Gene Therapy
Why Eli Lilly is Targeting Nav1.8 and MNK for Next-Gen Pain Therapeutics
Mastering AAV Cardiac Delivery: Serotypes, Promoters, and Ready-to-Use Models
Share
Top
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research